Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. (Record no. 28080313)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01406 a2200397 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517201605.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201809s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1757-790X |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1136/bcr-2017-223249 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Parker, Matthew Js |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20180912 |
| 245 00 - TITLE STATEMENT | |
| Title | Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | BMJ case reports |
| Date of publication, distribution, etc. | Feb 2018 |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Case Reports; Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Autoimmune Diseases |
| General subdivision | chemically induced |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | B7-H1 Antigen |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biopsy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Fasciitis |
| General subdivision | chemically induced |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunoglobulins, Intravenous |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunotherapy |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Magnetic Resonance Imaging |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Melanoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nivolumab |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Roberts, Mark E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lorigan, Paul C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | du Plessis, Daniel G |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chinoy, Hector |
| 773 0# - HOST ITEM ENTRY | |
| Title | BMJ case reports |
| Related parts | vol. 2018 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1136/bcr-2017-223249">https://doi.org/10.1136/bcr-2017-223249</a> |
| Public note | Available from publisher's website |
No items available.